Myriad Genetics (MYGN) Long-Term Investments (2010 - 2023)

Myriad Genetics has disclosed Long-Term Investments across 14 years of filings, most recently posting $6.2 million for Q2 2023.

• In Q2 2023, Long-Term Investments fell 92.1% year-over-year to $6.2 million; the TTM figure through Jun 2023 stood at $6.2 million (down 92.1% YoY), while the FY2022 annual figure was $54.8 million, down 7.12% from the prior year.
• Long-Term Investments slipped to $6.2 million in Q2 2023, from $30.4 million in the prior quarter.
• Over the last five years, Long-Term Investments for MYGN reached as high as $78.5 million in Q2 2022 and fell as low as $6.2 million in Q2 2023.
• The 5-year median for Long-Term Investments is $45.2 million (2020), against an average of $42.8 million.
• Annual changes were most pronounced in 2022 — Long-Term Investments soared 494.96% — and 2023, when it tumbled 92.1%.
• A 5-year view of Long-Term Investments shows it stood at $47.6 million in 2019, then plunged by 55.88% to $21.0 million in 2020, then jumped by 180.95% to $59.0 million in 2021, then retreated by 7.12% to $54.8 million in 2022, then tumbled by 88.69% to $6.2 million in 2023.
• According to Business Quant data, Long-Term Investments over the past three periods registered $6.2 million, $30.4 million, and $54.8 million for Q2 2023, Q1 2023, and Q4 2022 respectively.